Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver

Acad Radiol. 1996 Aug:3 Suppl 2:S417-9. doi: 10.1016/s1076-6332(96)80603-9.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adenoma, Liver Cell / diagnosis
  • Carcinoma, Hepatocellular / diagnosis
  • Cholangiocarcinoma / diagnosis
  • Contrast Media*
  • Dextrans
  • Dose-Response Relationship, Drug
  • Ferrosoferric Oxide
  • Hemangioma / diagnosis
  • Humans
  • Iron*
  • Liver Diseases / diagnosis*
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / secondary
  • Lymphoma / diagnosis
  • Magnetic Resonance Imaging*
  • Magnetite Nanoparticles
  • Oxides*
  • Sensitivity and Specificity

Substances

  • Contrast Media
  • Dextrans
  • Magnetite Nanoparticles
  • Oxides
  • Iron
  • ferumoxides
  • Ferrosoferric Oxide